This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

2014 FDA Drug Approval Decision Calendar

Updated as of Jan. 6, 2014.

For your biotech trading adventures in the new year -- an FDA drug approval calendar for 2014.

The following calendar includes 34 FDA drug approval decisions and scheduled advisory panels from December 2013 through October 2014. I compiled the calendar using company reports, my own research and the remarkably useful services of


January 2014: Drug approval decisions

Bristol-Myers Squibb 
Dapagliflozin for Type 2 diabetes
Jan. 14

Vanda Pharmaceuticals (VNDA)
Hetlioz for non-24 sleep disorder
Jan. 31

FDA advisory panels:

Chelsea Therapeutics (CHTP) 
Northera for orthostatic hypotension
Jan. 14

February 2014: Drug approval decisions

Chelsea Therapeutics
Northera for orthostatic hypotension
Feb. 14

Bristol-Myers Squibb
Metreleptin for lipodystrophy
Feb. 27

Biomarin (BMRN)
Vimizim for morquio syndrome
Feb. 28

Pharmacyclics (PCYC) and Johnson & Johnson (JNJ)
Imbruvica for chronic lymphocytic leukemia
Feb. 28

March 2014: Drug approval decisions

Celgene (CELG)
Apremilast for psoriatic arthritis
March 21

April 2014: Drug approval decisions

Biogen Idec
Alprolix for hemophilia B 
Jan. 3

MannKind (MNKD)
Afrezza for Type 1 and 2 diabetes
April 15

GlaxoSmithKline (GSK)
Abiglutide for diabetes
April 15

Santarus (SNTS)
Ruconest for hereditary angioedema
April 16

Pozen (POZN)
PA32540 & PA8140 for heart disease 
Jan. 24

Click ahead for more FDA drug approval decision dates

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CHTP $0.00 0.00%
GILD $89.00 0.90%
MNKD $1.45 7.41%
POZN $4.00 2.30%
OMER $13.25 0.00%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs